Sat, Jan 31, 2015, 11:25 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Alimera Sciences, Inc. (ALIM) Message Board

godwintom 6 posts  |  Last Activity: Jan 25, 2015 5:18 PM Member since: Dec 26, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Information please

    by stockaroo87 Jan 24, 2015 11:46 PM
    godwintom@att.net godwintom Jan 25, 2015 5:18 PM Flag

    I'm trying to determine their average per barrel cost?

  • Reply to

    Near term outlook for pSivida

    by godwintom Dec 26, 2014 1:46 PM
    godwintom@att.net godwintom Dec 29, 2014 1:02 PM Flag

    The enrollment will be complete by around the middle of 15 which means there is a full one year follow up on all participants so if all that works out we are looking at mid 16 and then submission of data to FDA has to be compiled. The actual filing of the NDA will come at earliest late 16 and expect some sort of reply by mid 17. This is based on one study as proposed by PSDV. Who know's what the actual time frame will be.

  • Reply to

    Near term outlook for pSivida

    by godwintom Dec 26, 2014 1:46 PM
    godwintom@att.net godwintom Dec 29, 2014 10:01 AM Flag

    Mick, you are right, I am jaded. But I'm not blinded by the possibility that PSDV may never be any more than they have been for the past 27 years. I'm still hoping and holding but disappointed with management style and results to date.

    Sentiment: Hold

  • Reply to

    Near term outlook for pSivida

    by godwintom Dec 26, 2014 1:46 PM
    godwintom@att.net godwintom Dec 28, 2014 2:57 PM Flag

    GSW, I would add shares at the 3.00- 3.25 range based on hard evidence as of today. The evidence is based on last reported sales in the U.K. and Germany and the apparent slow start in the rest of the E.U.. The future U.S. sales are unknown at this time primarily based on new products becoming available for this indication and I'm not certain that the FDA acceptance is what some have interpreted it to be, so I would ere on the side of caution. If E.U. sales pickup and the U.S. launch is impressive we could see robust s.p. improvement however if the opposite happens were in for a hard fall to 3.00 or under. Keep an eye on the qrtly report early Feb. from ALIM and also PSDV rev's from ALIM.

    Sentiment: Hold

  • Reply to

    Near term outlook for pSivida

    by godwintom Dec 26, 2014 1:46 PM
    godwintom@att.net godwintom Dec 27, 2014 2:10 PM Flag

    GSW, Sure there can be other catalyst but their announced emphasis has been on partnering with big money and low hanging fruit, which will probably not be as low hanging as we have been led to believe. Apparently much of their so called low hanging fruit has been in the form of staving off more demands from investors, such as the use of forward looking statements, namely, on the cusp, company transformation and inflection point to name a few. The other collaborations are just that and years away from the production of real money. If you would care to reread my post it does read (short) term and there should and will be many opportunities to reenter PSDV, as the track record clearly indicates. You mentioned day trader, where is that relevant in this discussion?, certainly not with me and congratulations on your paper profit, if you hold too long it could still be used for toilet paper. Not kool.

  • godwintom@att.net by godwintom Dec 26, 2014 1:46 PM Flag

    If ILUVIEN sales in the U.S. aren't moving along at a relatively brisk pace by mid 15, start bailing out of both PSDV & ALIM. The exception here would be for PSDV if they can sign a deal utilizing Tethadur. The Uveitis outcome is too distant to play without new product support from other players. Don't play the buyout theory at this point, there's not enough information or hype to support this. This management team needs to rethink their prospectus for adding new pharmas or bio tech's to their client roster. The hurry up and wait game can't last much longer.

ALIM
5.43-0.08(-1.45%)Jan 30 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.